Anja Haltner

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 8

Top Topics

Metastatic Breast Cancer

Systematic Review

Replacement Therapy

Multiple Myeloma

Top Venues

Current medical research and opinion

Journal of comparative effectiveness research

This page only lists publications with an associated author ORCID identifier.

Publications

Luciano J Costa, Parameswaran Hari, Jesus G Berdeja, Valerio De Stefano, Francesca Gay, Becky Hooper, Meaghan Bartlett, Anja Haltner, Emily Rosta, Shaji K Kumar, Thomas Martin, Maria-Victoria Mateos-Manteca, Philippe Moreau, Saad Z Usmani, Yunsi Olyslager, Jordan M Schecter, Tito Roccia, Ashraf Garrett, Sam Lee, Tonia Nesheiwat, Lida Pacaud, Changwei Zhou, Imtiaz A Samjoo, Yi Lin, Joris Diels, Satish Valluri, Katja Weisel
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. Current medical research and opinion 38 (10) (2022)
Tom Martin, Saad Z Usmani, Jordan M Schecter, Tito Roccia, Carolyn C Jackson, William Deraedt, Tzu-Min Yeh, Arnob Banerjee, Lida Pacaud, Ashraf Garrett, Meaghan Bartlett, Anja Haltner, Suzy Van Sanden, Joris Diels, Satish Valluri, Imtiaz A Samjoo
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current medical research and opinion (2022)
Tom Martin, Saad Z Usmani, Jordan M Schecter, Martin Vogel, Carolyn C Jackson, William Deraedt, Hong Tian, Tzu-Min Yeh, Arnob Banerjee, Lida Pacaud, Ashraf Garrett, Anja Haltner, Chris Cameron, Suzy Van Sanden, Joris Diels, Satish Valluri, Imtiaz A Samjoo
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current medical research and opinion 37 (10) (2021)
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, Paul Spin, Susan Lavinia Greco, Chris Cameron, Róisín Brennan, Frank Dahlke, Nicholas Adlard
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses. Current medical research and opinion 37 (11) (2021)
Hope S Rugo, Anja Haltner, Lin Zhan, Anh Tran, Eustratios Bananis, Becky Hooper, Debanjali Mitra, Chris Cameron
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. Journal of comparative effectiveness research 10 (6) (2021)
Ernest H Law, Roya Gavanji, Sarah Walsh, Anja Haltner, Rebecca McTavish, Chris Cameron
Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. Journal of comparative effectiveness research (2021)
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, Chris Cameron, Richard Nicholas, Frank Dahlke, Nicholas Adlard
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. Current medical research and opinion 36 (7) (2020)
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, Chris Cameron, Richard Nicholas, Nicolas Rouyrre, Frank Dahlke, Nicholas Adlard
Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Current medical research and opinion 36 (7) (2020)